Medicine, Media & Patients: A New Professional Language

journal

Panel Convened  at Annual Medical conference at NIAF

Scientists, journalists and cancer patients gathered to discuss the importance of precision medicine and accurate health and science communication during the National Italian American Foundation’s (NIAF) 44th Anniversary Gala Weekend in Washington, D.C.

“Medicine, Media, and Patients,” presented by Sbarro Health Research Organization (SHRO), included updates on precision medicine in oncology, an analysis of the state of health communication in Italy and America, as well as reflections from a former cancer patient.

The conference convened on Saturday, November 2, from 9 to 11:30 AM at the Omni Shoreham Hotel.

“As the Internet and social media assume greater importance in the communication of medical information, it’s vital for both researchers and journalists to ensure that this information is factually correct,” says Antonio Giordano, M.D., Ph.D., founder and director of SHRO.

The medical conference concluded with the annual Giovan Giacomo Giordano NIAF Award for Ethics and Creativity in Medical Research, presented by Giacomina Massaro-Giordano, M.D., professor of Opthalmology, Scheie Eye Institute, University of Pennsylvania.

Italian journalist Gerardo Ausiello of Il Mattino discussed the risks, limits and prospects of science communication in Italy, followed by freelance writer Ilene Raymond Rush, who writes regularly in the Philadelphia Inquirer, who talked about dealing with the contemporary mistrust of science and how health journalists might help remedy this problem.

“Our hope is that these journalists’ perspectives can shed light on ways that reporters and physicians can help consumers understand a variety of medical issues,” says Giordano. “We want to highlight how improving communication about our research can help to promote better health.”

Among the medical panelists participating was Professor Alfonso De Nicola, former medical director of the SSC Naples soccer team, and Dr. Raffaele Aiello, Director of the Omnia Lab and an expert in the field of infertility.

About the Sbarro Health Research Organization

The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org

Original Newswise release

SHRO Founder Presented with Career Award and Appointed Chair of Italian Cancer Association FONICAP

This slideshow requires JavaScript.

Sbarro Health Research Organization founder and Director, Antonio Giordano, M.D., Ph.D., has been recognized with a career award “for the great contributions he has made and which he will continue to make to science, medicine and research.” Giordano is director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University as well as a professor of Anatomic Pathology at the University of Siena.

The award was presented to Dr. Giordano on the final day of the second national congress organized by the AIC NET Foundation (Italian Alliance Against Thoraco-Pulmonary Neoplasms) and by the FONICAP Association (Operative National Interdisciplinary Force against Lung Cancer) in Verona, Italy.

In addition to the award, Dr. Giordano has been named chair of the FONICAP Association.

“It is with great pleasure that I accepted this new challenge,” says Giordano, “and I am eager to get work to complete the team of professionals who will join me in this adventure.”

Thoraco-pulmonary neoplasms represent a cause of high mortality in Italy and in western countries. Every year, 42,000 new cases occur in Italy and, unfortunately, a still too high percentage of these patients (30-40% and perhaps more) is not correctly treated.

The AIC NET Foundation and the associated scientific assistance platform FONICAP have created a new portal that provides a resource for patients, allowing them to take charge of a multidisciplinary approach to their treatment, exchange experiences, and the possibility of conducting national clinical studies within the FONICAP network.

Moreover, Professor Giordano was recently awarded the prestigious Cristoforo Colombo Prize for 2019 in New York, for the important results obtained in the field of cancer research and for the opportunities for study and work that he was able to create for many young Italian researchers. Presenting the award to Giordano was entrepreneur, philanthropist and president of Palermo Calcio, Tony Di Piazza, who took part in the ceremony along with representatives from the world of politics, finance, and entertainment.

About the Sbarro Health Research Organization

The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org

Original Newswise Release

Adding local anesthetics can improve treatment for incurable breast cancer, melanoma

A new study examined the effects of local anesthetics combined with standard chemotherapy for treatment of incurable triple-negative (TN) breast cancer, as well as melanoma. The results suggest that the combined treatment can lower the effective chemotherapy dosage, reduce side effects, improve tumor cell apoptosis, and reduce tumor cell migration.

Researchers at the Sbarro Health Research Organization (SHRO), at the Center for Biotechnology, Temple University, Philadelphia, and the University of L’Aquila, Italy, and the University of Siena, Italy, examined the effects of two anesthetics, ropivacaine and levobupivacaine, on two different human cancer cell lines, MDA-MB-231, triple-negative breast cancer, and A375, melanoma. This discovery may have important implications for the design of new drugs and therapeutic interventions for these recurrent and incurable tumors.

The findings were published September 20, 2019 in the Journal of Cellular Physiology.

Researchers are pursuing possible strategies for defeating TN breast cancer and melanoma by interfering with cell proliferation and apoptosis induction because these forms of cancer are notoriously difficult to treat. Building on the previously indicated effect of anesthetics in breast cancer cells and in other types of cancer in counteracting cell cycle progression, this study explores more in-depth how anesthetics may be used in cancer therapy, and the authors suggest further study is warranted.

“Our studies point towards a possible way to counteract tumor growth and recurrence by interfering with cell cycle progression, apoptosis induction, and migration.”

Annamaria Cimini of the University of L’Aquila, lead author of the study

“The design of new protocols with regional anesthetics may provide new perspectives for breast and melanoma therapies reducing cancer recurrence after surgery by counteracting their metastatic potential and resistance.”

Antonio Giordano, MD, PhD, founder and director of the Sbarro Institute for Cancer Research and Molecular Medicine

Journal reference:

Castelli, V. et al. (2019) Local anesthetics counteract cell proliferation and migration of human triple-negative breast cancer and melanoma cells. Journal of Cellular Physiologydoi.org/10.1002/jcp.29236.

 

Original Medical-News Posting

Untreatable Olive Tree Disease Can Be Contained, But Must Be Better Monitored, says SHRO Researcher

olive_tree 

Xylella fastidiosa, subsp. pauca is a bacterial pathogen currently devastating the olive orchards in Southern Italy (Apulia). Due to the epidemic, local production of olive oil has dropped by 90%, olive mills are shut down, the regional economy is suffering, and an invaluable cultural asset is compromised.

Keeping the epidemic under control requires the identification of infected plants in previously uninfected regions, and then taking the appropriate containment measures – i.e., uprooting of infected plants, as well as fighting the insect that spreads the bacterial infection.

In a new paper, prof. Enrico Bucci, from the Sbarro Health Research Organization (SHRO), proves how the current disease monitoring strategy is insufficient to identify all the infected plants, and thus allows the progression of the epidemic via undetected infection hotspots.

At the same time, Bucci shows how 98% of the infected olive trees cluster in spots of radius equal to 100-meters, thus providing a strong rationale for the current uprooting strategy, dictating eradication of all plants in a 100 meters radius around newly detected infected plants.

Moreover, since herbicide and insecticide treatments targeting the larval and adult vectors of the disease are independent of infected tree detection, the vector containment measures designed by the scientific community and dictated by the law are also strongly supported.

Given the current lack of any cure, containing the Xylella epidemic is a priority for preserving the traditional landscapes and the economies of the Mediterranean area: data published in this new paper on the effectiveness of the actions implemented to face the infection spreading are thus vital for finely tuning an appropriate containment strategy.

The SHRO and its researchers will always be at the forefront of the battle to save our environment from threats menacing humans, animals, and plants.

Bucci, E. M. Effectiveness of the monitoring of X. fastidiosa subsp. pauca in the olive orchards of Southern Italy (Apulia). Rend. Lincei. Sci. Fis. e Nat. (2019). doi:10.1007/s12210-019-00832-6

About the Sbarro Health Research Organization

The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org

 

Original Study          Original Newswise Release

Genetic Profiling and Personalized Training: Study Published in Collaboration between U.S. Researchers and the Medical Staff of the SSC Napoli

dna-soccer

A study recently published in the international scientific Journal of Cellular Physiology is the result of a collaboration between the Sbarro Health Research Organization (SHRO), a team of Italian researchers, and the Medical Staff of the SSC Napoli, one of the leading soccer clubs in Italy’s Serie A league.

The article, “Genomic analysis reveals association of specific SNPs with athletic performance and susceptibility to injuries in professional soccer players,” reports the impact of the personalized training programs and nutritional regimes adopted by physicians and trainers of the SSC Napoli in improving athletic performance and reducing the incidence of physical injuries. The results obtained were also confirmed in reports published by the Serie A league and by UEFA, which confirm that the SSC Napoli soccer players are among the “healthiest” in Europe. Moreover, the study also evaluated the presence of polymorphisms in five genes that intrinsically predispose toward a specific activity or to injuries, and in genes that can be externally modulated, for instance through specific nutrient supplementation.

The genomic variation profiling in the S.S.C. Naples soccer team uncovered that the potential genetic hindrances in some genes were minimized at least in part by the training and nutritional program designed by the team’s medical staff, thus explaining the excellent performance obtained by the team.

Dr. Alfonso De Nicola confirms: “This study represents an added value to the personalization of the athletic preparation that projects us fully towards the sports medicine of the third millennium.” The hypothesis reported suggest that the combination of appropriate training, adapted to the genetic and nutritional profile of each athlete, can in principle be a way to achieve elite athletic status and performance.

Prof. Antonio Giordano, director of the Sbarro Health Research Organization, emphasizes: “The new medicine of sport is becoming a specialty that increasingly takes into consideration the genetic differences of athletes.”

Dr. Raffaele Canonico concludes saying, “these parameters could be fundamental to adopt specific strategies aimed to improve, not only sports performance, but above all to protect the health of the athletes and make their careers more lasting.”

About the Sbarro Health Research Organization

The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org

Original Newswise Post

Oncolytic Viruses Against Mesothelioma: A Possible Weapon to Shrink Cancer and Boost the Antitumoral Immune Response

Mesothelioma is a deadly cancer mainly caused by exposure to asbestos or other toxic mineral fibers. Currently, there is no effective cure against this disease and life expectancy of patients with mesothelioma remains very low. Virotherapy, which is based on the use of viruses to fight cancer cells, has long been investigated as a possible antitumoral strategy. Oncolytic viruses, in particular, have the ability to lyse tumor cells and spread the infection locally. The recent approval by the Food & Drug Administration of an oncolytic virus for the treatment of melanoma, in 2015, has sparked a renewed interest in the field. Indeed, many pre-clinical and clinical studies are evaluating viral-based strategies against mesothelioma. Mesothelioma is particularly amenable to virotherapy because the pleural cavity provides an easy route to direct intratumoral injection eluding viral inactivation in the bloodstream and limiting off-target infection.

A new collaborative study from researchers of the National Cancer Institute of Naples, ‘Pascale Foundation’, Italy; the University of Naples ‘Federico II’; the University of Siena; and the Sbarro Institute for Cancer Research and Molecular Medicine in Philadelphia, PA, USA, explored the possible use of dl922-945, an adenovirus engineered to infect and replicate selectively in cancer cells, against mesothelioma. Adenovirus, a non-enveloped virus with a linear DNA genome, is among the oncolytic viruses most studied for therapeutic approaches. Adenovirus causes the common cold in humans or other diseases that are self-limited in immunocompetent hosts. It has a stable genome that does not mess up with the host genome and is able to self-replicate in the infected cells achieving a local high titer.

In this new study, published in Frontiers in Oncology, an open access peer-reviewed scientific journal, the authors showed that dl922-945 is able to infect and self-amplify within human mesothelioma cells, subverting their cell cycle features and inducing cancer cell death, an effect that is similarly triggered also in other cancer cell lines, such as those of the aggressive thyroid anaplastic carcinomas. The molecular mechanisms underlying dl922-945-induced cell demise, however, are still only partially characterized. In this study the authors showed that dl922-945 infection induces the exposure of calreticulin (an endoplasmic reticulum chaperone) on the surface of dying cells and the release of ATP and HMGB1, three hallmarks of the so called ‘immunogenic cell death’. In fact, the release of these molecules, along with tumor antigens from lysed cells, is crucial to activate a robust anti-tumoral immune response, so that dl922-945 has the potential to act as an in situ cancer vaccine against mesothelioma.

The authors also showed that dl922-947 infection reduces the production of two pro-angiogenic factors that contribute to tumor development, interleukin 8 and the vascular endothelial growth factor A, thereby further shaping the tumor microenvironment towards an antitumoral background.

“Virotherapy through dl922-947 synergized with the chemotherapy drug cisplatin in mesothelioma cell lines, suggesting that this approach could function along with the mainstay of treatment in the clinical setting,” says Carmelina A. Iannuzzi of the Pascale Foundation, who carried out this work as a PhD student at the University of Siena.

“dl922-947 treatment proved effective also in vivo, inhibiting the growth of mesothelioma xenografts, leading to complete tumor shrinkage in some mice and reducing the formation of intratumoral microvessels,” states Sarah Di Somma, co-first author of the study from the University of Naples.

“The ability of oncolytic viruses to reverse the tumor-induced immune tolerance through such modifications of the tumoral microenvironment is a major goal of current cancer therapies and yet another advantage of this class of antitumoral agents,” says Giuseppe Portella, virologist at the University of Naples who has characterized dl922-947 effects also in other tumor types.

“The next step will consist in assessing the potential of virotherapy in combination with the recently developed immune targeted therapies and translate these approaches to the clinical practice upon rigorous clinical trial testing,” says Francesca Pentimalli co-lead author of the study from the National Cancer Institute of Naples, which is under the Scientific Direction of Gerardo Botti, a renowned pathologist who is also a co-author of the study.

“Some studies predict an increase in the incidence of mesothelioma in some areas and therefore new therapeutic strategies able to cure or at least chronicize the disease are urgently needed,” concludes Antonio Giordano, Director and Founder of the Sbarro Institute who has devoted a great part of his latest efforts in findings novel approaches against mesothelioma, establishing dedicated research groups working in network across Naples, Siena, and Philadelphia.

About the Sbarro Health Research Organization

The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org

Original Newswise Release

Regulation of Cancer Promoting Molecule EphB4 Offers Potential Treatment Target for Mesothelioma, Other Cancers

A novel cancer-promoting molecular mechanism has been discovered by Pierluigi Scalia, M.D., Ph.D., with his co-workers at the Sbarro Institute for Cancer Research and Molecular Medicine, Division of Biology, Temple University, the Department of Medical Biotechnologies at University of Siena, Italy  and the Italian non-profit research organization ISOPROG, in collaboration with the Center of Biocomputational Sciences, part of the College of Science and Technology in Philadelphia.

The new discovery is described in a study published July 3, 2019 in the journal Oncogene, titled “Identification of a Novel EphB4 Phosphodegron Regulated by the Autocrine IGFII/IRA Axis in Malignant Mesothelioma.

“This study identifies a new potential targetable oncogenic mechanism, since it shows how a previously studied tumor self-stimulating signal regulates the function of a molecule known as EphB4, directly involved in malignant cellular behavior such as cancer blood vessels formation, normal tissue invasion and distant site metastasis,” Scalia says.

Scalia continues, “Interestingly, the key components of this newly identified molecular switch appear expressed in all malignant cancer cell lines studied, suggesting that the relevance of this mechanism might extend to many types of solid cancer, beyond mesothelioma.”

According to professor Antonio Giordano, M.D., Ph.D., co-author of the study and director of the Sbarro Institute, “this type of discovery is critical for deadly cancers like Malignant Mesothelioma for which the search for new molecular targets is highly invoked in the medical field due to the growing demand for new treatments towards more effective and personalized interventions.”

About the Sbarro Health Research Organization

The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org  

Oncogene Article            Original Newswise Post

New Natural Therapeutic Agent to Fight Diabetic Nephropathy

A team of researchers have published in the Journal of  Cellular Physiology that a new natural extract is able to inhibit the development of diabetic nephropathy, a kidney disease that is increasing in incidence throughout the world.

“The new extract of natural origin, obtained from red oranges and lemons, is rich in cyanidin 3-glucoside and other polyphenols,” says Prof. Roberto Ciarcia, MV, associate professor of Veterinary Pharmacology and Toxicology of the Department of Veterinary Medicine and Animal Production at the University of Naples Federico II. “This discovery opens new perspectives to limit kidney damage induced by type II diabetes mellitus and to block the development of diabetic nephropathy.”

The study, “A red orange and lemon by‐products extract rich in anthocyanins inhibits the progression of diabetic nephropathy,” first published online on May 29, 2019, describes how the extract successfully restored the blood glucose levels, body weight, and normalized oxidative stress on renal function in a test group of Zucker diabetic fatty rats.

The study authors include collaborators from the Department of Veterinary Medicine and Animal Production at the University Federico II of Naples and from the Sbarro Health Research Organization (SHRO), at the Center for Biotechnology, Temple University in Philadelphia.

“My research group, through the sophisticated technique of renal micropuncture conducted by Sara Damiano, first author  of the study, has evaluated at the tubular level the mechanism involved during diabetic nephropathy and has discovered an important protective effect of this new extract,” says Prof. Salvatore Florio, full professor of Veterinary Pharmacology and Toxicology of the Department of Veterinary Medicine and Animal Production at the University of Naples Federico II. “It is important to underline that this compound was obtained in collaboration with the Council for Agricultural Research and Economics, Research Center for Olive, Citrus and Tree Fruit, Acireale.”

“The ability of the new extract to reduce the renal damage is remarkable, considering that diabetic nephropathy could induce kidney failure. We hope that this new extract can be a useful compound to fight the progression of diabetic nephropathy and allow an improvement in the quality of life of patients with type II diabetes mellitus,” concludes Damiano.

About the Sbarro Health Research Organization

The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org

 

Original Newswise Post           Journal of Cellular Physiology Article       PubMed Abstract

Exploiting RB1 Predictive Value for Cancer Therapy in the Clinical Setting: Lost in Translation

Newswise — The RB1 protein, named after the pediatric tumor retinoblastoma, was discovered in the 80s as the first tumor suppressor and, since then, its pathway has been found inactivated in most human cancers. RB1 ability to halt tumor development and growth has been mainly ascribed to its function in cell cycle regulation, which directly restrains cell division and proliferation. However, besides this canonical role, RB1 has a multitude of other functions, which profoundly affect the destiny of a cell by regulating stemness, differentiation, senescence, and even cell death. Indeed, RB1 status emerged not only as a key factor in cancer development and progression, but also as a crucial determinant of cell fate in response to various anticancer treatments. The idea of tailoring antitumoral strategies based on the patient’s RB1 status has shown potential, but its translation to the clinical setting has proved challenging.

A new commentary article, published last week in Biochemical Pharmacology, discusses many of these challenges and the importance of evaluating the status of RB1 in clinical specimens to support therapeutic decisions. The article provides a thorough overview of studies analyzing the key role of RB1 in the response to different anticancer approaches, spanning both cytotoxic (i.e. chemotherapy and radiotherapy) and cytostatic strategies (i.e. hormonal therapy) routinely used in the clinic. The authors also address the relationship of RB1 status to the effectiveness of targeted agents, such as protein kinase inhibitors including the new generation of highly selective inhibitors of the CDK4/6 cell cycle kinases, and also immunotherapeutics, which are among the most promising alternatives to conventional therapies.

“Through both canonical and non-canonical mechanisms, RB1 exerts opposite effects on the response to cytotoxic and cytostatic agents, limiting the effectiveness of cytotoxic chemotherapy and radiotherapy agents and sensitizing the cells to cytostatic hormone treatments and kinase inhibitor-based therapies,” says Paola Indovina of the Sbarro Health Research Organization at Temple University in Philadelphia (www.shro.org), first author of the article. “Moreover, the recently identified role of RB1 in immune function likely impacts the patient response to immunotherapy and other anticancer strategies.”

“Although a great amount of evidence pointed to the crucial importance of assessing RB1 status in the clinical setting, which could help to select patients who can benefit from a particular treatment, while sparing non-responders the unnecessary side effects, its predictive value is still underused mainly owing to the complexity of RB1 function and to difficulties in evaluating its functional status and context-dependent roles,” says Francesca Pentimalli, a coauthor working at the National Cancer Institute of Naples, Pascale Foundation.

“For the successful translation of RB1 predictive power in the clinical practice, it is crucial to dissect the molecular mechanisms whereby RB1, and its family members, regulate context-specific responses to the wide range of possible antitumoral strategies and to develop rigorous and standardized methods for their evaluation in clinical specimens,” says Antonio Giordano, Director and Founder of the Sbarro Health Research Organization, Professor of Pathological Anatomy at the University of Siena, Italy, who first identified one of the members of the retinoblastoma family, the RBL2 /p130 protein, and contributed to define the role of these proteins in cancer and cell cycle regulation.

About the Sbarro Health Research Organization

The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org

 

Original Newswise Post      Original Study

Cervical Cancer During Pregnancy, Though Serious, is Highly Treatable According to New Research Review

Newswise — A team of researchers in the Gynecologic Oncology Unit of the University Hospital of Bologna, in collaboration with Professor Antonio Giordano from the Sbarro Health Research Organization, has published a revision of the literature about cases of cervical cancer in pregnancy, with the addition of new cases treated at the University Hospital of Bologna. Their work appears in the Journal of Cellular Physiology.

“Cancer during pregnancy is defined as a tumor diagnosed in pregnant women, or in the immediate postpartum,” says Myriam Perrone MD, PhD of the Gynecologic Oncologic Unit and first author of the manuscript. “In the last decade, we observed an increase in incidence of this condition, largely due to later childbearing, and although it has been hypothesized that hormones and growth factors necessary for fetal development may accelerate tumor growth, evidence suggests that pregnancy is not necessarily a poor prognostic factor for patients’ survival.

“Cervical cancer is the second most common form of cancer or pre-cancer diagnosed during pregnancy or postpartum, and occurs in approximately 0.004-0.1% of pregnant women. The rarity of the condition makes large trial studies impossible, and guidelines up to now are based on small case and expert opinions,” Perrone concludes.

“For these reasons, today, diagnostic tools and treatment are similar in pregnant and non pregnant women, with some differences,” explains Alessandro Bovicelli, MD, PhD of the Gynecologic Oncology Unit of the University of Bologna and co-author of the manuscript. “In pregnant women, conservative surgery can be proposed as primary treatment of early stage cervical cancer, such as cone and lymphadenectomy. However, in women with advanced stage, neoadjuvant chemotherapy is a possible option of treatment.”

“Individualized therapies are strongly recommended and the treatment decision should be made collaboratively with a multidisciplinary team consisting of obstetricians, gynecologists, oncologists, pediatricians, and psychologists,” adds Professor Pierandrea De Iaco, Director of Gynecologic Oncology Unit of University Hospital of Bologna. “Over the years and with the publication of new studies, the treatment strategy has gradually changed to a more conservative treatment, particularly for patients in second or third trimester with early stage cancer. Furthermore, it has been reported that neoadjuvant chemotherapy has been successful at controlling the disease and delaying delivery until fetal maturity, without serious adverse effects on the mother and foetus.

“Time of delivery must be evaluated with obstetricians, as the point of fetal maturity is the main issue,” concludes De Iaco.

“Cancer in pregnancy is not an acute emergency and clinicians should take all the time necessary to study the case and offer the best diagnosis and therapy,” says Perrone. “Treatment of patients with cancer in pregnancy should be offered in gynecologic oncology centers associated with experienced perinatal centers to provide patients with expertise in all needed aspects.

“In the future, the development of molecular markers and their routine use could help in the clinical decision making,” concludes Perrone.

About the Sbarro Health Research Organization

The Sbarro Health Research Organization (SHRO) is non-profit charity committed to funding excellence in basic genetic research to cure and diagnose cancer, cardiovascular diseases, diabetes and other chronic illnesses and to foster the training of young doctors in a spirit of professionalism and humanism. To learn more about the SHRO please visit www.shro.org

Original Newswise Release          Journal Article